Triple-combo of drugs targeting pancreatic cancer looks to human trials
New preclinical work has found a combination of three experimental immunotherapy drugs could help shrink pancreatic tumors. Each of the drugs have demonstrated safety in early human trials and the hope is to begin testing the triple combo by the end 2021. Source of Article